+357 96 030922
info@marketpublishers.com

Non-alcoholic Steatohepatitis Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, Others), By End User (Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes), By Region and Competition, 2020-2030F

https://marketpublishers.com/r/NFDEA8AE259FEN.html
Date: June 2025
Pages: 183
Price: US$ 4,500.00 (Single User License)
ID: NFDEA8AE259FEN

Abstracts

Market Overview

The Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market was valued at USD 1.81 Billion in 2024 and is projected to reach USD 6.27 Billion by 2030, growing at a CAGR of 22.97%. Rising global prevalence of metabolic disorders—including obesity, insulin resistance, and type 2 diabetes—continues to accelerate the demand for non-invasive and reliable diagnostic tools for NASH. As non-alcoholic fatty liver disease (NAFLD) advances toward NASH in many patients, the limitations of liver biopsy, such as invasiveness and sampling variability, have driven interest in biomarker-based diagnostics. These biomarkers enable early detection, disease staging, and therapeutic monitoring. With over 115 million people estimated to be affected by NASH globally, there is an urgent need for scalable diagnostic alternatives. The pharmaceutical industry is leveraging biomarkers for patient stratification and efficacy tracking in clinical trials. Technological advancements in multi-omics platforms—such as proteomics, metabolomics, and transcriptomics—along with AI-driven analytics, are transforming biomarker development and enabling precision medicine. This market is further supported by cross-sector collaborations that focus on integrated diagnostic solutions,

+357 96 030922
info@marketpublishers.com

combining imaging, blood-based markers, and digital platforms.

Key Market Drivers

Rising Prevalence of Metabolic Disorders and NASH Progression

The growing incidence of metabolic conditions such as obesity, insulin resistance, dyslipidemia, hypertension, and type 2 diabetes is significantly boosting the Global NASH Biomarkers Market. Data from the ICMR INDIAB study and NFHS 5 reveal concerning rates of obesity and diabetes, particularly among younger adults, further expanding the at-risk population. As NAFLD progresses silently to NASH, non-invasive biomarker-based diagnostics are gaining traction for early identification and risk assessment. Unlike liver biopsies, biomarkers offer repeatable, safer, and scalable alternatives for detecting liver inflammation and fibrosis. These tools are becoming essential in both clinical care and clinical research, where they enable real-time disease monitoring, guide therapy adjustments, and improve clinical trial design by supporting patient selection and endpoint analysis. The increasing use of multi-biomarker panels—spanning serum, genetic, and imaging data—is enabling more precise diagnosis and advancing the clinical utility of NASH biomarkers in both preventive and therapeutic strategies.

Key Market Challenges

Lack of Standardization and Clinical Validation

A major constraint for the NASH biomarker market is the lack of standardization and widespread clinical validation. Despite a growing pool of potential biomarkers, few have achieved regulatory approval or consistent use in clinical practice due to variability in study outcomes, assay formats, and patient heterogeneity. This inconsistency makes it difficult for physicians to rely on biomarker data as definitive diagnostic or prognostic tools, reinforcing dependence on liver biopsy. Furthermore, regulatory agencies demand high standards of accuracy, reproducibility, and clinical correlation, which are challenging to meet without robust, multi-phase clinical validation. Fragmentation across research efforts—where academic institutions and companies pursue proprietary solutions—further hinders the development of universal standards and complicates comparative evaluation. This lack of harmonization delays market entry and restricts biomarker adoption, requiring coordinated global frameworks and collaborative initiatives to ensure consistency, validation, and data interoperability across platforms and studies.

+357 96 030922
info@marketpublishers.com

Key Market Trends

Emergence of Multi-Omics-Based Biomarker Discovery

The growing adoption of multi-omics approaches is reshaping the NASH biomarker landscape by offering a comprehensive understanding of disease mechanisms. Unlike traditional methods that rely on single markers, multi-omics strategies integrate genomic, proteomic, metabolomic, lipidomic, and transcriptomic data to identify complex biomarker signatures. These approaches allow for more accurate differentiation between NAFLD, early-stage NASH, and advanced fibrosis. Metabolomics and lipidomics, in particular, uncover liver-specific metabolic dysfunctions, while transcriptomic profiling helps detect gene expression patterns linked to hepatic inflammation and stress. As these datasets are processed using AI and machine learning, researchers can generate robust biomarker panels tailored to disease subtypes and progression stages. This trend supports personalized diagnostics, better disease stratification, and targeted therapy monitoring, making multi-omics tools essential in advancing non-invasive, high-precision NASH diagnostics.

Key Market Players

GENFIT SA

Prometheus Laboratories Inc.

Siemens Healthineers AG

BioPredictive S.A.S.

Quest Diagnostics Incorporated

AstraZeneca PLC

Exalenz Bioscience Ltd. (Meridian Bioscience, Inc.)

Laboratory Corporation of America Holdings

Pfizer Inc.

+357 96 030922
info@marketpublishers.com

Bristol-Myers Squibb Company

Report Scope

In this report, the Global Non-alcoholic Steatohepatitis Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-alcoholic Steatohepatitis Biomarkers Market, By Type:

Serum Biomarkers

Hepatic Fibrosis Biomarkers

Apoptosis Biomarkers

Oxidative Stress Biomarkers

Others

Non-alcoholic Steatohepatitis Biomarkers Market, By End User:

Pharma & Cro Industry

Hospitals

Diagnostic Labs

Academic Research Institutes

Non-alcoholic Steatohepatitis Biomarkers Market, By Region:

North America

United States

Canada

+357 96 030922
info@marketpublishers.com

- Mexico

Europe

- France
- United Kingdom
- Italy
- Germany
- Spain

Asia-Pacific

- China
- India
- Japan
- Australia
- South Korea

South America

- Brazil
- Argentina
- Colombia

Middle East & Africa

- South Africa
- Saudi Arabia

+357 96 030922
info@marketpublishers.com

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-alcoholic Steatohepatitis Biomarkers Market.

Available Customizations

Global Non-alcoholic Steatohepatitis Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

+357 96 030922
info@marketpublishers.com

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. VOICE OF CUSTOMER

5. GLOBAL NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, Others)
  5.2.2. By End User (Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic

+357 96 030922
info@marketpublishers.com

Research Institutes)
5.2.3. By Company (2024)
5.2.4. By Region
5.3. Market Map

6. NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET OUTLOOK

6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By End User
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Non-alcoholic Steatohepatitis Biomarkers Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By End User
6.3.2. Mexico Non-alcoholic Steatohepatitis Biomarkers Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By End User
6.3.3. Canada Non-alcoholic Steatohepatitis Biomarkers Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By End User

7. EUROPE NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET OUTLOOK

7.1. Market Size & Forecast
7.1.1. By Value

+357 96 030922
info@marketpublishers.com

7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By End User
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Non-alcoholic Steatohepatitis Biomarkers Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By End User
7.3.2. Germany Non-alcoholic Steatohepatitis Biomarkers Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By End User
7.3.3. United Kingdom Non-alcoholic Steatohepatitis Biomarkers Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By End User
7.3.4. Italy Non-alcoholic Steatohepatitis Biomarkers Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By End User
7.3.5. Spain Non-alcoholic Steatohepatitis Biomarkers Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By End User

8. ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET OUTLOOK

+357 96 030922
info@marketpublishers.com

8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By End User
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Non-alcoholic Steatohepatitis Biomarkers Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By End User
8.3.2. India Non-alcoholic Steatohepatitis Biomarkers Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By End User
8.3.3. South Korea Non-alcoholic Steatohepatitis Biomarkers Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By End User
8.3.4. Japan Non-alcoholic Steatohepatitis Biomarkers Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By End User
8.3.5. Australia Non-alcoholic Steatohepatitis Biomarkers Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By End User

9. SOUTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS

+357 96 030922
info@marketpublishers.com

MARKET OUTLOOK

9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By End User
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Non-alcoholic Steatohepatitis Biomarkers Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By End User
9.3.2. Argentina Non-alcoholic Steatohepatitis Biomarkers Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By End User
9.3.3. Colombia Non-alcoholic Steatohepatitis Biomarkers Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By End User

10. MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS BIOMARKERS MARKET OUTLOOK

10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By End User
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Non-alcoholic Steatohepatitis Biomarkers Market Outlook

+357 96 030922
info@marketpublishers.com

10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By End User
10.3.2. Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By End User
10.3.3. UAE Non-alcoholic Steatohepatitis Biomarkers Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By End User

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. DISRUPTIONS: CONFLICTS, PANDEMICS AND TRADE BARRIERS

14. PORTERS FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

+357 96 030922
info@marketpublishers.com

15. COMPETITIVE LANDSCAPE

15.1. GENFIT SA
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Prometheus Laboratories Inc.
15.3. Siemens Healthineers AG
15.4. BioPredictive S.A.S.
15.5. Quest Diagnostics Incorporated
15.6. AstraZeneca PLC
15.7. Exalenz Bioscience Ltd.(Meridian Bioscience, Inc.)
15.8. Laboratory Corporation of America Holdings
15.9. Pfizer Inc.
15.10. Bristol-Myers Squibb Company

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Non-alcoholic Steatohepatitis Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, Others), By End User (Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes), By Region and Competition, 2020-2030F

Product link: https://marketpublishers.com/r/NFDEA8AE259FEN.html

Price: US$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/NFDEA8AE259FEN.html